At the same conference, Biodel also reported findings from a preclinical study exploring the effect of disodium EDTA concentration in VIAject?® (ultra-rapid-acting injectable human insulin) on the drug's speed of action in diabetic pigs.  EDTA is one of two key excipients used in VIAject?® which affect the rapid dissociation of insulin hexamers into monomers and the subsequent rapid absorption of insulin.  In a poster presentation, Dr. Roderike Pohl and colleagues from Biodel described results of a study of eight diabetic pigs showed that reduced amounts of EDTA produced  lower insulin concentrations and less rapid absorption of insulin, although the duration of insulin action remained essentially the same regardless of the EDTA concentration.  The authors concluded that the study demonstrated a systematic relationship between the concentration of EDTA and the speed of absorption, confirming that sufficient EDTA is required to achieve the ultra-rapid absorption profile and pharmacodynamic action of VIAject?®.

Abstracts summarizing the oral presentation by Ms. Kashyap ("Smart" Basal Insulin Formulation That Releases Insulin in Response to Blood Glucose Concentrations of Diabetic Swine) and the poster presentation by Dr. Pohl (Effect of EDTA Concentration on Ultra-Rapid Action of VIAject?® in Diabetic Miniature Swine) are available on Biodel's website, www.biodel.  

SOURCE Biodel Inc.